Down Syndrome-Associated Arthritis (DA): Diagnostic and Management Challenges

Area of Science:

• Genetics and Immunology
• Pediatric Rheumatology

Background:

• Down syndrome (DS), caused by trisomy 21, presents with diverse symptoms, including immune dysregulation.
• Immune dysregulation in DS increases the risk of autoimmune diseases, notably Down syndrome-associated arthritis (DA).
• DA is characterized by aggressive, polyarticular, rheumatoid factor-negative arthritis with early joint damage.

Purpose of the Study:

• To review current literature on Down syndrome-associated arthritis in children and adolescents.
• To focus on the presentation, diagnosis, and management of DA.
• To identify barriers to optimal care for DA patients.

Main Methods:

• Systematic review of existing literature on DA.
• Analysis of clinical presentation, diagnostic challenges, and treatment outcomes.
• Identification of gaps in screening, monitoring, and therapeutic guidelines.

Main Results:

• Delayed diagnosis of DA is common due to lack of formal screening guidelines.
• DA often presents aggressively with significant bone and joint damage.
• Management is challenging, with many patients requiring multiple lines of therapy and experiencing toxicity or ineffectiveness.

Conclusions:

• There is a critical need for formal screening and monitoring guidelines for inflammatory arthritis in individuals with DS.
• Optimizing the management of DA requires addressing treatment challenges, including medication toxicity and efficacy.
• Further research and guideline development are essential to improve care and outcomes for children and adolescents with DA.